Journal of Clinical Oncology
Articles in this Issue
Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer, including early-onset disease.
547 Background: Accurate risk stratification in early breast cancer (eBC) is critical to guide adjuvant treatment intensit...
Electronic nicotine delivery systems versus combustible cigarettes: A systematic review and meta-analysis of biomarkers of harm from randomized controlled trials.
e22520 Background: Electronic nicotine delivery systems (ENDS) advertised harm reduction, yet their long-term oncologic an...
Atrial fibrillation in hematologic malignancies: A systematic review and meta-analysis.
e24018 Background: Atrial fibrillation (AF) affects approximately 1-2% of the general adult population, with incidence rat...
A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator’s choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).
TPS8136 Background: Small Cell Lung Cancer (SCLC) is a neuroendocrine tumor with high proliferation rate, early metastasis...
An NCDB analysis on the demographic, treatment, and survival of nonkeratinizing small cell squamous cell carcinoma.
e20147 Background: Nonkeratinizing small cell squamous cell carcinoma (NSCSCC), ICD-O-3 code-8073, is a malignant epitheli...
Evaluating the efficacy and mechanisms of action of seriniquinone against pediatric neuroblastoma.
e15125 Background: Children diagnosed with neuroblastoma face poor prognosis despite aggressive multimodal therapies, high...
Impact of leukocytosis on outcomes in patients with myelofibrosis: A propensity-matched analysis.
e18608 Background: Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) that is characterized by bone marrow fibrosis...
Guidance conformance of mainstream germline cancer testing by oncology providers in the Veterans Health Administration.
e13571 Background: Mainstream germline testing, where oncology providers obtain consent and order testing directly, facili...
Adoption of Bayesian Optimal Interval (BOIN) design in phase I oncology trials, trends, and challenges.
e23006 Background: Traditionally, the 3+3 design (also known as classic design) has been the most widely used design in Ph...
Transcriptome-wide profiling of antibody–drug conjugate (ADC) targets across solid tumors with IHC validation in a sub-cohort.
e15177 Background: The expanding use of ADCs and other expression-driven therapies requires biomarker assessment beyond DN...
A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.
TPS5143 Background: Outcomes for patients (pts) with mCRPC after androgen receptor pathway inhibitors (ARPI) remain poor....
Epidemiological trends and burden of esophageal cancer mortality in South Asia: A retrospective analysis from 1990 to 2023 with advanced machine learning forecasting to 2050.
e16055 Background: Esophageal cancer remains a major cause of cancer mortality in South Asia, with marked geographic and s...
Transcriptomic profiling in advanced hepatocellular carcinoma to identify biomarkers for immunotherapy response and mechanisms of acquired resistance.
4146 Background: Immune checkpoint inhibitors (ICI) are the standard of care for advanced HCC, yet validated biomarkers fo...
Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
e16564 Background: Urothelial carcinoma (UC) predominantly affects older adults with a high burden of comorbidities, parti...
Efficacy and safety of ivonescimab combined with liposomal irinotecan in patients with small-cell lung cancer (SCLC) progressing after first-line chemoimmunotherapy: A multicenter, phase 2 study.
8007 Background: SCLC patients (pts) progressing after first-line platinum-based chemoimmunotherapy have limited effective...
Impact of concomitant medications on immune checkpoint inhibitor outcomes in sarcoma.
11553 Background: Immune checkpoint inhibitors (ICIs) are an established treatment for many malignancies, with an emerging...
Breast cancer risk in MSH2 and MSH6 Lynch syndrome female patients: A single-institution retrospective analysis.
e22655 Background: Lynch syndrome (LS) is a germ pathogenic mutations involving DNA Mismatch Repair (MMR) genes and is ass...
Differential impact of <i>TP53</i> and <i>KRAS</i> pathogenic variants on overall survival in advanced ovarian carcinoma.
5583 Background: Advanced epithelial ovarian carcinoma, including high grade serous ovarian carcinoma (HGSOC), clear cell...
Neoadjuvant (NA) chemoradiotherapy (CTRT) plus avelumab (Ave) in locally advanced rectal cancer (LARC): 4-year outcomes of the phase II AVANA trial and their association with computational pathology.
3632 Background: The AVANA trial investigated the addition of PD-L1 inhibitor Ave to NA CTRT in LARC. Here, we report long...
Geographic variation in outcomes and resource utilization among U.S. hospitalizations for tumor lysis syndrome.
e13718 Background: Tumor lysis syndrome (TLS) is a life threatening oncologic emergency. Geographic differences in U.S. ho...
Velzatinib (IDRX-42) as 1L or 2L therapy for advanced gastrointestinal stromal tumors (GISTs) by <i>KIT</i> mutation status: A subset analysis of the phase 1/1b StrateGIST 1 study.
11501 Background: Most GISTs present with activating KIT mutations (exons 9/11) in...
Profile and clinical outcomes of patients with thoracic tumors discussed at a tumor board in Brazil.
e23137 Background: The thoracic oncology tumor board is a multidisciplinary forum essential for discussing and defining th...
Real-world use of fruquintinib in refractory metastatic colorectal cancer in the United States.
e15713 Background: Fruquintinib demonstrated overall survival benefit in heavily pretreated metastatic colorectal cancer (...
An early resistance genomic state (ERGS) as an identifier of primary CDK4/6 inhibitor failure in HR+/HER2− metastatic breast cancer.
1086 Background: CDK4/6 inhibitors combined with endocrine therapy are the standard first-line treatment for patients with...
RACED: Reduction of cervical cancer disparities— Racial literacy as a strategy to foster a race-conscious oncology.
e13609 Background: The RACED project aims to reduce racial inequities in cervical cancer care at the Instituto do Câncer d...